Logo

Santhera to Present Result of DELOS & SYROS Study at the 2019 MDA Clinical and Scientific Conference

Share this

Santhera to Present Result of DELOS & SYROS Study at the 2019 MDA Clinical and Scientific Conference

Shots:

  • The P-III DELOS study involves assessing of Idebenone (900 mg/day) vs PBO in 64 patients with Duchenne muscular dystrophy (DMD) for 52wks. & P-II DELPHI study with 2-year extension study (DELPHI-E). SYROS study involves assessing of Idebenone (900 mg/day) in 18 patients under Expanded Access Programs (EAPs) who completed the DELOS study
  • The P-III Delos study resulted in meeting 1EP as slow loss of respiratory function. The Syros study resulted in long-term & consistent long-term reduction in rate of respiratory function & maintained up-to 6yrs.
  • Idebenone is a synthetic benzoquinone & a cofactor for the enzyme NAD(P)H: quinone oxidoreductase (NQO1) capable of stimulating mitochondrial electron transport- reducing and scavenging reactive oxygen species (ROS) and supplementing cellular energy levels

Ref: Santhera | Image: Twitter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions